A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™ 5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix

• Women aged 18 years and above

• Confirmed cervical infection with HPV types 16 and/or 18 at screening

• Cervical tissue specimen/slides provided to Study Pathology Adjudication Committee for diagnosis scheduled to be collected within 10 weeks prior to anticipated date of first dose of study drug

• Confirmed histologic evidence of cervical HSIL at screening

• Must be judged by Investigator to be an appropriate candidate for the protocol-specified procedure required at Week 36

• With respect to their reproductive capacity must be post-menopausal or surgically sterile or willing to use a contraceptive method with failure rate of less than 1% per year when used consistently and correctly from screening until Week 36

• Normal screening electrocardiogram (ECG)